Samsung Bioepis Agrees Not to Sell Enbrel Copy Amid Patent Suit

Amgen and Roche reached an agreement that will prevent Samsung Bioepis from marketing copies of the blockbuster arthritis drug Enbrel for an unspecified period while a patent-infringement lawsuit makes its way through the courts.

• Bioepis won’t sell Eticovo, its biosimilar version of Enbrel, or any product containing the fusion protein called etanercept, “subject to the terms and conditions” of a sealed agreement, according to injunction approved Wednesday in federal court in Newark, New Jersey
• A spokeswoman for Amgen confirmed the agreement includes an injunction but declined to provide further details
• Representatives of Bioepis didn’t immediately respond to a request for ...